Positives

• A 2014 placebo-controlled study of 1,050 mg/day American skullcap (Scutellaria lateriflora) for 2 weeks in 43 people reported significant improvements in mood compared with placebo, supporting use for the anxiety-overlap subset of Long COVID and ME/CFS Healthline.
  
  
• A 56-day blue skullcap supplementation trial in primary insomnia patients significantly improved sleep quality and several sleep parameters compared with placebo Herbal Reality.
  
  

Negatives

• Patients on skullcap have developed clinically apparent liver injury and at least one drug-induced autoimmune hepatitis case, with onset typically 1-12 weeks after starting NIH LiverTox.
• One patient on a Chinese skullcap and black catechu joint-pain preparation developed acute hepatitis, illustrating that combination products carry layered risk Wiley.
• Patients commonly describe stomach pain, constipation, vomiting, and stomach upset, and some report stimulant-like rather than sedating effects despite using it for sleep WebMD.
• Patients chasing anxiety relief on skullcap commonly see no benefit beyond placebo response, with the herb showing no significant anxiety reduction over placebo on the primary outcome despite mood improvement Healthline.

Hurdles & Side Effects

• Adulteration is a real product-quality issue — phytochemical analysis of suspected hepatotoxicity cases identified germander contamination or species mislabeling, so cheap bottles may contain something other than skullcap entirely PMC.
• North American (Scutellaria lateriflora) and Chinese (Scutellaria baicalensis) skullcap are different species with different risk profiles and different effects, and labels often blur the distinction Drugs.com.